SAN FRANCISCO, CA--(Marketwired - March 31, 2016) - It takes extraordinary dexterity to execute a strategic merger, and then to take first steps toward positioning a new molecular entity for a Phase 3 drug trial and potential partnership with a big pharma. That's exactly the inflection point at which Diffusion Pharmaceuticals Inc. (
The Life Sciences Report : David, let's talk about your clinical program. The Diffusion platform is designed to oxygenate tumor tissues with trans sodium crocetinate prior to conventional therapies. The hypothesis is that oxygenation of the tissues makes tumor cells more vulnerable to radiation and chemotherapy. Does this premise rest on the theory that tumor cells are a) more aggressive in a hypoxic environment, or b) that rapidly proliferating tumor cells are outrunning their blood supply, therefore making them less capable of receiving therapeutic agents via bloodstream?
David Kalergis: What we think is it's "b," which leads to "a." The inherent hypoxic nature of the tumor tissue outgrowing its blood supply then begins to select for more aggressive cells that have evolved to thrive in what would otherwise be an oxygen-deprived, hostile environment. That low-oxygen environment confers treatment resistance on these cancer cells. When you do not have a sufficient amount of free oxygen in the cell to support the killing power of radiation and chemo, those cells that have survived begin to thrive, and they evolve toward a...
Continue reading this interview: Diffusion Pharmaceuticals Takes Aim at Brain Cancer: CEO David Kalergis
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
Diffusion Pharmaceuticals Inc. is a sponsor of Streetwise Reports. David Kalergis had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Kalergis and not of Streetwise Reports or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
Please see Streetwise Reports' terms of use and full legal disclaimer.
Contact Information:
Jim Patrick